ALDR - Alder BioPharmaceuticals® to Present at the 8th Annual SVB Leerink Global Healthcare Conference
BOTHELL, Wash., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder’s president and chief executive officer, will provide a business overview and update at the 8th Annual SVB Leerink Global Healthcare Conference at 11:00 am ET on Thursday, February 28, 2019 in New York, NY.
The presentation will be webcast live on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contact:
Michael Schaffzin
Stern Investor Relations, Inc.
212.362.1200
michael@sternir.com
Media Contact:
Ashley Cadle
TogoRun
a.cadle@togorun.com
310.463.0143